PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation

Documenti analoghi

• PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations
  di: Ji, Mei, et al.
  Pubblicazione: (2016)
• Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
  di: Jia, Yijun, et al.
  Pubblicazione: (2020)
• Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
  di: Cai, Yiran, et al.
  Pubblicazione: (2020)
• PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment
  di: Chang, Cheng-Yu, et al.
  Pubblicazione: (2021)
• EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
  di: Dong, Zhong-Yi, et al.
  Pubblicazione: (2017)